Ossium Health to Exhibit at Significant Scientific Meetings
SAN FRANCISCO--Ossium Health, a leading bioengineering company, has announced its participation in the upcoming Transplantation & Cellular Therapy (Tandem) Meetings organized by ASTCT and CIBMTR. This event will take place shortly and promises to be a pivotal platform for sharing advancements in the field of hematopoietic stem cells and related therapies.
Visit Ossium Health at Booth 629
Attendees are encouraged to stop by Ossium Health at Booth 629. This is an excellent opportunity to learn about the company's innovative developments within the hematopoietic sector. Ossium Health is dedicated to advancing stem cell therapies that could potentially change the treatment landscape for patients facing severe health challenges.
Exciting Trials and Programs
At the exhibit, visitors can gain insights into two key initiatives:
PRESERVE I Clinical Trial
The PRESERVE I Clinical Trial is currently in progress and actively recruiting patients. This trial aims to assess the effectiveness of allogeneic hematopoietic cell transplantation (HCT) utilizing Ossium’s organ donor bone marrow for patients diagnosed with hematologic malignancies.
HOPE Program
In addition, Ossium’s HOPE Program provides expanded access for patients requiring allogeneic HCT who are not eligible to participate in the PRESERVE I trial. This commitment exemplifies Ossium Health’s dedication to making treatments accessible to those in need.
Poster Presentations at the Event
Ossium Health will also present research findings at the event, specifically focusing on Poster 221. This poster, titled A Potency Assay Matrix for Establishing Consistency of Manufactured Mesenchymal Stem/Stromal Cells, will be featured on Thursday during a dedicated session focused on the regulatory aspects and processing considerations related to cellular and gene therapies.
About Ossium Health
Founded in 2016, Ossium Health has emerged as a trailblazer in the bioengineering space. The company utilizes a proprietary organ donor bone marrow banking platform to develop stem cell therapies aimed at addressing life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Led by Kevin Caldwell, Chief Executive Officer, and Erik Woods, Chief Science Officer, Ossium Health operates a manufacturing facility that is registered with the FDA and a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).
To gather more information about Ossium Health and its programs, you can visit their official website. They are also active on professional networks such as LinkedIn and social media platforms like X.
Frequently Asked Questions
What is the goal of the PRESERVE I Clinical Trial?
The PRESERVE I Clinical Trial aims to evaluate the effectiveness of using Ossium’s organ donor bone marrow for treating patients with hematologic malignancies.
Where can I find Ossium Health at the conference?
You can visit Ossium Health at Booth 629 for more information and insights on their research and developments.
What is the HOPE Program?
The HOPE Program offers expanded access to allogeneic HCT for patients who are unable to enroll in ongoing clinical trials, ensuring they still receive critical treatment.
Is Ossium Health involved in any poster presentations at the event?
Yes, Ossium Health will be presenting findings related to a potency assay matrix for stem cells in their Poster 221 presentation.
Who are the key leaders at Ossium Health?
The company is led by CEO Kevin Caldwell and Chief Science Officer Erik Woods, who both co-founded the company in 2016.
